Clinical validation of 18F-AZD4694, an amyloid-β-specific PET radioligand

Journal of Nuclear Medicine

Volumn 53, Issue 3, 2012, Pages 415-424

  Cselényi, Zsolt ^a,b   Jönhagen, Maria Eriksdotter ^b,c   Forsberg, Anton ^b   Halldin, Christer ^b   Julin, Per ^a   Schou, Magnus ^a,b   Johnström, Peter ^a,b   Varnäs, Katarina ^b   Svensson, Samuel ^a   Farde, Lars ^a,b  

^a ASTRAZENECA R AND D   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

18F; Alzheimer's disease; Amyloid beta; PET; Radioligand

Indexed keywords

AMYLOID BETA PROTEIN; AZD 4694 F 18; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; AZD4694; BENZOFURAN DERIVATIVE; DIAGNOSTIC AGENT; FLUORINATED HYDROCARBON;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN REGION; CEREBELLUM; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG UPTAKE; FEMALE; HUMAN; ISOTOPE TRACING; MALE; METABOLITE; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN DETERMINATION; QUANTITATIVE STUDY; RADIOACTIVITY; RADIOASSAY; REPRODUCIBILITY; TEST RETEST RELIABILITY; TISSUE DISTRIBUTION; ARTERY; BRAIN CIRCULATION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; IMAGE PROCESSING; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; METHODOLOGY; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; PROTEIN BINDING; PSYCHOLOGICAL ASPECT; SCINTISCANNING; STATISTICAL MODEL;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ARTERIES; BENZOFURANS; CEREBROVASCULAR CIRCULATION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FEMALE; HUMANS; HYDROCARBONS, FLUORINATED; IMAGE PROCESSING, COMPUTER-ASSISTED; INJECTIONS, INTRAVENOUS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MODELS, STATISTICAL; NEUROPSYCHOLOGICAL TESTS; POSITRON-EMISSION TOMOGRAPHY; PROTEIN BINDING; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS;

EID: 84858607421     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.111.094029     Document Type: Article

References (38)

1. Ikonomovic MD, Klunk W, Abrahamson E, et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain. 2008;131:1630-1645. (Pubitemid 351806448)
2. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol. 2004;55:306-319. (Pubitemid 38269583)
3. Forsberg A, Engler H, Almkvist O, et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging. 2008;29:1456-1465.
4. Villemagne VL, Pike KE, Chételat G, et al. Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease. Ann Neurol. 2011;69:181-192.
5. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol. 2010;9:363-372.
6. Blomquist G, Engler H, Nordberg A, et al. Unidirectional influx and net accumulation of PIB. Open Neuroimag J. 2008;2:114-125.
7. Lopresti BJ, Klunk W, Mathis C, et al. Simplified quantification of Pittsburgh compound B amyloid imaging PET studies: a comparative analysis. J Nucl Med. 2005;46:1959-1972. (Pubitemid 46657441)
8. 11C] raclopride binding to D2-dopamine receptors studied by PET: a comparison to the equilibrium analysis. J Cereb Blood Flow Metab. 1989;9:696-708.
9. 18F- flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol. 2010;68:319-329.
10. Clark CM, Schneider JA, Bedell BJ, et al. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA. 2011;305:275-283.
11. Barthel H, Luthardt J, Becker G, et al. Individualized quantification of brain β-amyloid burden: results of a proof of mechanism phase 0 florbetaben PET trial in patients with Alzheimer's disease and healthy controls. Eur J Nucl Med Mol Imaging. 2011;38:1702-1714.
12. 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease. J Nucl Med. 2009;50:1251-1259.
13. Juréus A, Swahn BM, Sandell J, et al. Characterization of AZD4694, a novel fluorinated Abeta plaque neuroimaging PET radioligand. J Neurochem. 2010;114: 784-794.
14. Allen F. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV. Washington, DC: American Psychiatric Association; 1994.
15. Varrone A, Sjöholm N, Eriksson L, Gulyás B, Halldin C, Farde L. Advancement in PET quantification using 3D-OP-OSEM point spread function reconstruction with the HRRT. Eur J Nucl Med Mol Imaging. 2009;36:1639-1650.
16. Halldin C, Farde L, Högberg T, et al. Carbon-11-FLB 457: a radioligand for extrastriatal D2 dopamine receptors. J Nucl Med. 1995;36:1275-1281.
17. Roland PE, Zilles K. Brain atlases: a new research tool. Trends Neurosci. 1994;17:458-467. (Pubitemid 24321944)
18. Svarer C, Madsen K, Hasselbalch SG, et al. MR-based automatic delineation of volumes of interest in human brain PET images using probability maps. Neuro-image. 2005;24:969-979. (Pubitemid 40164499)
19. Cselényi Z, Olsson H, Halldin C, Gulyás B, Farde L. A comparison of recent parametric neuroreceptor mapping approaches based on measurements with the high affinity PET radioligands [11C]FLB 457 and [11C]WAY 100635. Neuroimage. 2006;32:1690-1708. (Pubitemid 44332262)
20. 11C-methyl]-(2)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab. 1990;10:740-747.
21. Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab. 1996;16:834-840. (Pubitemid 26292051)
22. Cselényi Z, Olsson H, Farde L, Gulyás B. Wavelet-aided parametric mapping of cerebral dopamine D2 receptors using the high affinity PET radioligand [11C] FLB 457. Neuroimage. 2002;17:47-60.
23. Lammertsma AA, Hume SP. Simplified reference tissue model for PET receptor studies. Neuroimage. 1996;4:153-158.
24. Thie JA. Understanding the standardized uptake value, its methods, and implications for usage. J Nucl Med. 2004;45:1431-1434. (Pubitemid 47618494)
25. 11C]FLB 457 binding to extrastriatal dopamine receptors in the human brain. J Cereb Blood Flow Metab. 1999;19:1164-1173.
26. Akaike H. A new look at statistical model identification. IEEE Trans Automatic Control. 1974:716-723.
27. Shrout PE, Fleiss JL. Intraclass correlations: uses in assessing rater reliability. Psychol Bull. 1979;86:420-428.
28. 11C]PIB-amyloid binding and levels of Abeta40 and Abeta42 in postmortem brain tissue from Alzheimer patients. Neurochem Int. 2009;54:347-357.
29. Price JC, Klunk W, Lopresti B, et al. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh compound-B. J Cereb Blood Flow Metab. 2005;25:1528-1547. (Pubitemid 41541962)
30. 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol. 2008;7:129-135.
31. 18F-AV-45 (florbetapir F 18). J Nucl Med. 2010;51:913-920.
32. Farde L, Ito H, Swahn CG, Pike VW, Halldin C. Quantitative analyses of carbonyl- carbon-11-WAY-100635 binding to central 5-hydroxytryptamine-1A receptors in man. J Nucl Med. 1998;39:1965-1971. (Pubitemid 28518900)
33. 11C]PIB studies. Neuroimage. 2008;42:76-86.
34. Gunn RN, Lammertsma AA, Hume SP, Cunningham VJ. Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. Neuroimage. 1997;6:279-287. (Pubitemid 28018717)
35. 18F] cyclofoxy and positron emission tomography. J Cereb Blood Flow Metab. 1993;13:24-42.
36. Olsson H, Farde L. Potentials and pitfalls using high affinity radioligands in PET and SPET determinations on regional drug induced D2 receptor occupancy: a simulation study based on experimental data. Neuroimage. 2001;14:936-945. (Pubitemid 32929894)
37. Drzezga A, Grimmer T, Henriksen G, et al. Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease. Neurology. 2009;72: 1487-1494.
38. Bourgeat P, Chételat G, Villemagne V, et al. Beta-amyloid burden in the temporal neocortex is related to hippocampal atrophy in elderly subjects without dementia. Neurology. 2010;74:121-127.